The Lawn Mower® 4.0 by MANSCAPED™ Now Available Internationally
21.7.2021 15:00:00 CEST | Business Wire | Press Release
You ready to rock the landscaped look? Let’s get mowin’. Today, MANSCAPED™, the global leader and category creator of men’s below-the-waist grooming, announces the international launch of its fourth-generation electric trimmer, The Lawn Mower® 4.0. Designed and engineered specifically for groin and body grooming, the brand’s newest masterpiece focuses on intelligent functionality, maximum performance and, of course, a superior below-the-waist grooming experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210721005277/en/
The moment you’ve all been waiting for. Men around the world can now get their hands on MANSCAPED’s fourth-generation groin and body trimmer. (Graphic: Business Wire)
What’s more, The Lawn Mower 4.0 has been integrated into MANSCAPED’s thoughtfully curated bundles for the ultimate self-care routine. The hotly anticipated device and newly elevated kits are now shipping to the United Kingdom, the European Union, Norway, Switzerland, Australia, and New Zealand, in addition to the United States and Canada.
“The global launch of The Lawn Mower 4.0 and our newest packages means getting our latest and most exciting innovations into the hands of millions of men all over the world,” said Paul Tran, Founder and CEO of MANSCAPED. “It’s milestones like these that further advance our vision of driving the movement that changes the face of male grooming — something we’re both humbled by and proud to do every day and with every launch.”
What can you expect with the latest and greatest debuting from the global grooming giant? We’re glad you asked...
The Lawn Mower® 4.0 Groin Trimmer
Proven product attributes and state-of-the-art upgrades come together to make this tool the marquee groin and body trimmer on the market.
Core Features:
- SkinSafe® technology to help reduce the risk of nicks, snags, and tugs
- Powerful 7,000 RPM motor with QuietStroke™ technology
- Rechargeable 600 mAh li-ion battery
- Waterproof design for convenient wet or dry operation
New Enhancements:
- Wireless charging system with electromagnetic induction
- 4000k LED spotlight with diffuser so you can see where you’re trimming
- Cutting-edge ceramic blade to help reduce grooming accidents
- Adjustable trimming guard sizes 1 to 4, with 3, 6, 10, or 13mm settings
- Modern two-toned black finish and powerful packaging presentation
- Travel lock for safety - and racking up frequent flier miles
To up-level your grooming game, or give the greatest gift ever, consider exploring MANSCAPED’s luxury kits that combine The Lawn Mower 4.0 with an array of other top-selling tools, formulations, and accessories. When used together, cleanliness and confidence are abounding.
- The Lawn Mower 4.0 Groin Trimmer
- Crop Preserver® Ball Deodorant- Avoid stenchy under regions and the dreaded “swamp crotch”; infused with cooling aloe vera, this formulation helps combat sweat and unwanted odor down there
- Crop Reviver® Ball Toner- This spray is the solution for maintaining hygiene and freshness, especially when on-the-go; relieve high-friction areas and post-shave irritation with just a spritz
- This bundle’s free gifts include The Shed premium travel bag and the much acclaimed MANSCAPED™ Boxers made with a microfiber blend
Add another essential men's grooming tool into the mix with this kit featuring MANSCAPED’s premier above-the-waist tool.
- The Weed Whacker® Nose & Ear Hair Trimmer- MANSCAPED redesigned the traditional nose hair taming device by focusing on the highest performance and comfort; equipped with SkinSafe technology, a 9,000 RPM motor, and 360-degree rotary dual-blade system
- The Lawn Mower 4.0 Groin Trimmer
- Crop Preserver Ball Deodorant
- Crop Reviver Ball Toner
- The Shed & MANSCAPED Boxers
To learn more and to purchase any of these new products or packages, visit MANSCAPED.com, a one-stop-shop destination website designed for customers in the United Kingdom, European Union, Norway, Switzerland, Australia, New Zealand, Canada and more regions to come this year.
About MANSCAPED™:
Founded by Paul Tran in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist, trusted by over 2 million men worldwide. The product range includes only the best tools, formulations, and accessories for a simple, effective, and elevated male grooming routine. MANSCAPED offers a one-stop-shop at manscaped.com and direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, the European Union, Norway, and Switzerland. Select products and unique bundles can also be found on Amazon with Prime and pickup options available. Retail placement includes Target, Best Buy, and Macy’s stores throughout the U.S. and Hairhouse locations in Australia. For more information, visit the website or follow on Facebook, Instagram, Twitter, TikTok, YouTube, and Triller.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005277/en/
Contact information
MANSCAPED, Inc.
Allison Frazier, Director of Public Relations
allison@manscaped.com
925-216-2791
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom